| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Beta Bionics, Inc.: Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 29.10. | Beta Bionics raises 2025 revenue guidance to $96.5M and projects Q4 gross margin improvement amid pharmacy channel expansion | 1 | Seeking Alpha | ||
| 28.10. | Beta Bionics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 28.10. | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | 975 | GlobeNewswire (Europe) | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| 28.10. | Beta Bionics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.10. | Stifel resumes Beta Bionics stock coverage with Buy rating on iLet adoption | 1 | Investing.com | ||
| BETA BIONICS Aktie jetzt für 0€ handeln | |||||
| 20.10. | Stifel: Kaufempfehlung für Beta Bionics dank starker iLet-Marktakzeptanz | 3 | Investing.com Deutsch | ||
| 17.10. | Beta Bionics stock reaffirmed Buy at Truist Securities on strong growth outlook | 1 | Investing.com | ||
| 09.10. | Beta Bionics, Inc.: Beta Bionics to Announce Third Quarter 2025 Financial Results on October 28, 2025 | 2 | GlobeNewswire (USA) | ||
| 01.10. | Forecasting The Future: 4 Analyst Projections For Beta Bionics | 1 | Benzinga.com | ||
| 01.10. | Wachstum bei Diabetestechnologie: Goldman Sachs stuft Beta Bionics auf "Buy" hoch | 6 | Investing.com Deutsch | ||
| 01.10. | Goldman Sachs upgrades Beta Bionics stock to Buy on diabetes tech growth | 2 | Investing.com | ||
| 30.07. | Beyond The Numbers: 6 Analysts Discuss Beta Bionics Stock | 2 | Benzinga.com | ||
| 30.07. | Beta Bionics stock price target raised to $21 by Truist on strong revenue | 2 | Investing.com | ||
| 29.07. | Beta Bionics GAAP EPS of -$0.39 beats by $0.08, revenue of $23.2M beats by $3.51M | 14 | Seeking Alpha | ||
| 29.07. | Beta Bionics Q2 2025 presentation: Revenue soars to $23.2M, guidance raised | 1 | Investing.com | ||
| 29.07. | Beta Bionics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.07. | Beta Bionics, Inc.: Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | 801 | GlobeNewswire (Europe) | IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| 02.07. | Beta Bionics, Inc.: Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025 | 2 | GlobeNewswire (USA) | ||
| 23.06. | BBNX Stock May Gain From Abbott Deal to Advance iLet Integration | 3 | Zacks |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,050 | -1,63 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| HIMS & HERS HEALTH | 31,480 | -0,69 % | Hims & Hers Health, Inc: Hims & Hers Brings Comprehensive Weight Loss Programme to the UK | Expansion Debuts Hers, Unlocking Personalised Care for British WomenLONDON, Dec. 10, 2025 /PRNewswire/ -- Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive... ► Artikel lesen | |
| RADNET | 66,50 | +5,56 % | RadNet, Inc.: GE HealthCare and RadNet's DeepHealth Division Sign Letter of Intent to Advance Innovation and Adoption of AI-Powered Imaging Across Multiple Modalities and Remote Scanning | Collaboration aims to expand existing U.S. relationship combining GE HealthCare's mammography systems with DeepHealth's Breast Suite to include a worldwide distribution arrangementIntends to integrate... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 35,990 | -0,11 % | UBS stuft Procept BioRobotics mit "Buy" ein - Wachstum bei Systemauslastung als Treiber | ||
| BRIGHTSPRING HEALTH SERVICES | 36,540 | +1,78 % | BrightSpring upgraded at KeyBanc on specialty pharmacy and EBITDA prospects | ||
| INFUSYSTEM | 7,000 | -4,11 % | InfuSystem Holdings, Inc - 8-K, Current Report | ||
| IRADIMED | 84,00 | +2,44 % | iRadimed declares $0.50 special dividend | ||
| KESTRA MEDICAL TECHNOLOGIES | 26,240 | +5,34 % | Kestra Medical Technologies, Ltd.: Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results | KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,030 | +0,94 % | Starke Kursanstiege - AJN Resources, Delivery Hero, Siemens Healthineers | Ein massiver Stellenabbau betrifft nicht nur die deutsche Wirtschaft, auch in der Schweiz sind Umstrukturierungen erforderlich, um sich den Marktgegebenheiten anzupassen. Nach der überstürzten Übernahme... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,130 | +0,53 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| FRESENIUS | 47,560 | -0,73 % | AKTIEN IM FOKUS: Medizintechnikwerte von Exane bewegt - 'Zweigeteiltes 2026' | FRANKFURT (dpa-AFX) - Die Aktien von Siemens Healthineers und Sartorius haben am Mittwoch nach einer Studie von Exane BNP Paribas zum europäischen Medizintechniksektor unterschiedliche Richtungen eingeschlagen.... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,360 | -0,31 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 40,580 | +1,45 % | Carl Zeiss Meditec: Ein Top-Turnaroundkandidat für 2026! | Die Aktie des Medizingeräteherstellers Carl Zeiss Meditec blickt auf ein schwaches Börsenjahr zurück. Doch schon das kommende Jahr könnte die Wende bringen. Carl Zeiss Meditec: Ein Underperformer vor... ► Artikel lesen | |
| GERRESHEIMER | 28,040 | +6,62 % | Gerresheimer AG: Strukturelle Herausforderungen bestehen weiterhin in der Branche. Kursziel gesenkt; Halten. | Gerresheimer (GXI) bleibt strukturell belastet in einem sich abschwächenden Markt für pharmazeutische Verpackungen. Schott Pharma, ein naher Wettbewerber, berichtete von einer rückläufigen Nachfrage... ► Artikel lesen | |
| GENEDX | 151,32 | -2,61 % | GeneDx and Guardant Health named as BTIG's top picks for 2026 |